Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Alteration of Serum Malondialdehyde Level As Biomarker of Oxidative Stress during Acute Myeloid Leukemia Treatment

Alzbeta Hlavackova, PhD, Jan Vydra, MD, Leona Chrastinova, PhD, Roman Kotlin, PhD, Jana Stikarova, PhD, Jiri Suttnar, PhD, Jan E. Dyr, Prof.

Blood (2019) 134 (Supplement_1): 5181.

https://doi.org/10.1182/blood-2019-122303

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia

Gautam Borthakur, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Keyur Patel, MD PhD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Musa Yilmaz, MD, Zeev E. Estrov, MD, Maro N. Ohanian, DO, Rita Maduike, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 3993.

https://doi.org/10.1182/blood-2018-99-118591

Published: 2018

Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD

Blood (2018) 132 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2018-99-116485

Published: 2018

Journal Articles

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Miriam Marquis, PhD, Cyrielle Beaubois, Vincent-Philippe Lavallee, MD, Michal Abrahamowicz, PhD, Coraline Danieli, PhD, Sébastien Lemieux, PhD, Imran Ahmad, MD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephen B Ting, MD PhD, Shaun Fleming, MBBS(Hons) FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, William Grey, PhD, David Grimwade, MD PhD, Robert K. Hills, DPhil, Paresh Vyas, MD PhD, Nigel H. Russell, MD, Guy Sauvageau, MD, PhD, Josee Hebert, MD

Blood (2017) 130 (Supplement 1): 1402.

https://doi.org/10.1182/blood.V130.Suppl_1.1402.1402

Published: 2017

Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD

Blood (2017) 130 (Supplement 1): 3874.

https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874

Published: 2017

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Blood (2016) 128 (22): 1639.

https://doi.org/10.1182/blood.V128.22.1639.1639

Published: 2016

Journal Articles

Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Blood (2016) 128 (22): 895.

https://doi.org/10.1182/blood.V128.22.895.895

Published: 2016

Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 897.

https://doi.org/10.1182/blood.V128.22.897.897

Published: 2016

Journal Articles

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Lionel Ades, MD PhD, Xavier Thomas, MD PhD, Agnès Guerci, MD PhD, Arnaud Pigneux, MD, Norbert Vey, Emmanuel Raffoux, MD, Sylvie Castaigne, MD PhD, Olivier Spertini, Dominique Bron, MD PhD, Jean Pierre Marolleau, MD PhD, Gandhi Damaj, MD, Dominique Bordessoule, MD PhD, Julie Lejeune, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 898.

https://doi.org/10.1182/blood.V128.22.898.898

Published: 2016

Journal Articles

Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia

Seung-Hwan Shin, MD, Seung-Ah Yahng, MD, Jae-Ho Yoon, MD, Byung-Sik Cho, MD, Hee-Je Kim, MD, Young-Woo Jeon, MD, Sung-Eun Lee, MD, Ki-Sung Eom, MD, Yoo-Jin Kim, MD, Seok Lee, MD, Chang-Ki Min, MD, Seok-Goo Cho, MD, Dong-Wook Kim, Jong-Wook Lee, MD, Woo-Sung Min, MD

Blood (2015) 126 (23): 1338.

https://doi.org/10.1182/blood.V126.23.1338.1338

Published: 2015

Journal Articles

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2541.

https://doi.org/10.1182/blood.V126.23.2541.2541

Published: 2015

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

NARROW

Alteration of Serum Malondialdehyde Level As Biomarker of Oxidative Stress during Acute Myeloid Leukemia Treatment

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only